as of 11-17-2026 3:45pm EST
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 2.2B | IPO Year: | 2025 |
| Target Price: | $65.00 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.63 | EPS Growth: | 82.37 |
| 52 Week Low/High: | $20.13 - $60.66 | Next Earning Date: | 11-12-2026 |
| Revenue: | $176,034,000 | Revenue Growth: | 39.92% |
| Revenue Growth (this year): | 49.74% | Revenue Growth (next year): | 24.54% |
| P/E Ratio: | -74.38 | Index: | |
| Free Cash Flow: | -59048000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Executive Officer
Avg Cost/Share
$55.74
Shares
38,900
Total Value
$2,168,286.00
Owned After
251,983
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$53.15
Shares
3,587
Total Value
$190,649.05
Owned After
149,587
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$55.01
Shares
23,933
Total Value
$1,316,554.33
Owned After
73,453
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$49.57
Shares
38,900
Total Value
$1,928,195.20
Owned After
251,983
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$50.03
Shares
6,640
Total Value
$332,211.82
Owned After
149,587
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$49.69
Shares
27,540
Total Value
$1,368,470.86
Owned After
149,587
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$50.60
Shares
5,876
Total Value
$297,325.60
Owned After
149,587
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$50.00
Shares
27,230
Total Value
$1,361,500.00
Owned After
251,983
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Farquhar John C.M. | HTFL | Chief Executive Officer | Nov 10, 2026 | Sell | $55.74 | 38,900 | $2,168,286.00 | 251,983 | |
| Verghese Vikram | HTFL | Chief Financial Officer | Nov 9, 2026 | Sell | $53.15 | 3,587 | $190,649.05 | 149,587 | |
| Rogers Campbell | HTFL | Chief Medical Officer | Oct 22, 2026 | Sell | $55.01 | 23,933 | $1,316,554.33 | 73,453 | |
| Farquhar John C.M. | HTFL | Chief Executive Officer | Oct 12, 2026 | Sell | $49.57 | 38,900 | $1,928,195.20 | 251,983 | |
| Verghese Vikram | HTFL | Chief Financial Officer | Sep 8, 2026 | Sell | $50.03 | 6,640 | $332,211.82 | 149,587 | |
| Verghese Vikram | HTFL | Chief Financial Officer | Sep 3, 2026 | Sell | $49.69 | 27,540 | $1,368,470.86 | 149,587 | |
| Verghese Vikram | HTFL | Chief Financial Officer | Sep 2, 2026 | Sell | $50.60 | 5,876 | $297,325.60 | 149,587 | |
| Farquhar John C.M. | HTFL | Chief Executive Officer | Aug 21, 2026 | Sell | $50.00 | 27,230 | $1,361,500.00 | 251,983 |
SEC 8-K filings with transcript text
Nov 12, 2026 · 100% conf.
1D
+14.47%
$68.36
Act: -18.78%
5D
+21.90%
$72.80
20D
+28.83%
$76.94
2 htfl-20261112xex99_1.htm
Exhibit 991 20261112
Exhibit 99.1
Heartflow Reports Third Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
SAN FRANCISCO — November 12, 2026 – Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today reported financial results for the third quarter ended September 30, 2026.
Third Quarter 2026 Highlights
Ï
Total revenue of $72.9 million, a 57% increase year-over-year
Ï
Gross margin of 83.6%, non-GAAP gross margin of 83.8%
Ï
Net operating loss of $13.8 million; non-GAAP net operating loss of $5.0 million
2026 Annual Guidance
Ï
Total revenue of $262 million to $264 million (approximately 49% to 50% growth year-over-year), compared to previous guidance of $246 million to $250 million (approximately 40% to 42% growth year-over-year)
Ï
Non-GAAP gross margin of approximately 82.5%, compared to previous guidance of approximately 82%
“Our third quarter was excellent, with revenue accelerating for the third consecutive quarter and U.S. revenue growing at its fastest pace in 11 quarters,” said John Farquhar, President and CEO of Heartflow. “Our core FFRCT business remains durable, our installed base continues to expand rapidly, and activations of Heartflow Plaque Analysis are ramping ahead of plan, with utilization broadening across a wider share of applicable CCTAs. The CCTA market continues to grow rapidly and remains significantly underpenetrated. Strong performance across our diagnostic platform, along with disciplined execution of our commercial, innovation and clinical initiatives, gives us the confidence to raise our 2026 guidance once again. With continued momentum and a scaling business, we believe we are well-positioned to extend our market leadership, and we have increased confidence in our path to profitability.”
Third Quarter 2026 Financial Results
Total revenue was $72.9 million, a 57% increase year-over-year. U.S. revenue was $67.9 million, a 60% increase year-over-year. International and other revenue was $4.9 million, a 29% increase year-over-year. The year-over-year increase in total global revenue was primarily attributable to an increase in total U.S. FFRCT revenue case volume and an increase in total U.S. Plaque revenue case volume.
Gross profit was $60.9 million, compared to $35.4 million in the prior year period. Non-GAAP gross profit was $61.1 million, compared to $35.5 million in the prior year period.
Gross margin was 83.6%, compared to 76.5% in the prior year period. Non-GAAP gross margin was 83.8%, compared to 76.8% in the prior year period. The year-over-year gross margin expansion was primarily attributable to an increase in total revenue case volume, an increase in total U.S. Plaque revenue case volume, and improved production team productivity driven by AI efficiency initiatives, partially offset by the hiring and training of production team personnel.
Total operating expenses were $74.8 million, or 103% of total revenue, compared to $50.5 million, or 109% of total revenue, in the prior year period. Non-GAAP total operating expenses were $66.1 million, or 91% of total revenue, compared to $46.7 million, or 101% of total revenue, in the prior year period. The year-over-year operating expense increase was primarily attributable to increased investment in sales personnel and related expenses, as well as increased investments in technology and clinical research.
Net operating loss was $13.8 million, compared to $15.1 million in the prior year period. Non-GAAP net operating loss was $5.0 million, compared to $11.1 million in the prior year period.
Net loss was $11.5 million, or ($0.13) net loss per share, compared to $50.9 million, or ($1.04) net loss per share, in the prior year period. Net loss in the prior year period included a $32.1 million noncash charge from the remeasurement of the fair value of the Company’s warrant liability, a $4.8 million noncash benefit from the remeasurement of the fair value of the Company’s derivative liability, and a $6.4 million loss on extinguishment of debt from the full prepayment of the Company’s term loan in August 2025.
Non-GAAP net loss was $2.7 million, or ($0.03) non-GAAP net loss per share, compared to $13.2 million, or ($0.27) non-GAAP net loss per share, in the prior year period.
Adjusted EBITDA was ($3.6) million, compared to ($9.8) million in the prior year period.
Cash, cash equivalents and investments totaled $253.0 million as of September 30, 2026.
For additional information regarding non-GAAP financial measures, see “Use of Non-GAAP Measures,” “Heartflow GAAP to Non-GAAP Reconciliations” and “Reconciliation of GAAP Net Loss to Adjusted EBITDA” below.
Webcast and Conference Call Details
Heartflow will host a conference call today, November 12, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its third quarter 2026 financial results. Those interested in listening
Aug 13, 2026
May 14, 2026
2 htfl-20260514xex99_1.htm
Exhibit 99.1 2026.05.14
Exhibit 99.1
Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
SAN FRANCISCO — May 14, 2026 – Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the first quarter ended March 31, 2026.
First Quarter 2026 Highlights
·
Total revenue of $52.6 million, a 41% increase year-over-year
·
Gross margin of 80.2%, non-GAAP gross margin of 80.5%
·
Net operating loss of $29.5 million, including a $7.5 million non-cash impairment charge associated with facilities optimization and headquarters relocation to San Francisco. Non-GAAP net operating loss was $15.5 million
2026 Annual Guidance
·
Total revenue of $228 million to $232 million (approximately 29% to 32% growth year-over-year), compared to previous guidance of $218 million to $222 million (approximately 24% to 26% growth year-over-year)
·
Non-GAAP gross margin of approximately 81%, compared to previous guidance of 80% to 81%
“Heartflow entered 2026 with unprecedented momentum, expanding the category leadership we established over the last several years,” said John Farquhar, President and CEO of Heartflow. “Our AI-driven platform, deeply embedded commercial footprint, and the world’s largest database that recently expanded to over 200 million annotated CCTA images combine to create a foundational advantage that grows stronger with every quarter. The growth of our core FFRCT business remains durable, and adoption of Heartflow Plaque Analysis is ramping ahead of schedule. Most importantly, by helping physicians guide the care of over 650,000 patients worldwide, Heartflow has achieved an unrivaled scale of real-world experience. As the architects of this category, we continue to extend our leadership position, becoming the AI operating system of record for the detection, diagnosis, management, and treatment planning of coronary artery disease.”
First Quarter 2026 Financial Results
Total revenue was $52.6 million, a 41% increase year-over-year. U.S. revenue was $48.3 million, a 42% increase year-over-year. International and other revenue was $4.3 million, a 34% increase year-over-year. The year-over-year increase in total global revenue was primarily attributable to an increase in total U.S. FFRCT volume.
Gross profit was $42.2 million, compared to $27.9 million in the prior year period. Non-GAAP gross profit was $42.3 million, compared to $28.0 million in the prior year period.
Gross margin was 80.2%, compared to 75.1% in the prior year period. Non-GAAP gross margin was 80.5%, compared to 75.3% in the prior year period. The year-over-year gross margin expansion was primarily attributable to an increase in revenue case volume and improved production team productivity driven by AI efficiency initiatives, partially offset by the hiring and training of production team personnel.
Total operating expenses were $71.7 million, or 136% of total revenue, compared to $45.4 million, or 122% of total revenue, in the prior year period. GAAP operating expenses also included a $7.5 million non-cash impairment charge related to the right-of-use asset for our Mountain View, California facility. The Company optimized its facilities footprint and relocated its headquarters to San Francisco. Non-GAAP total operating expenses were $57.8 million, or 110% of total revenue, compared to $43.0 million, or 116% of total revenue, in the prior year period. The year-over-year operating expense increase was primarily attributable to increased investment in sales personnel and related expenses, as well as increased investments in technology and clinical research.
Net operating loss was $29.5 million, compared to $17.5 million in the prior year period. Non-GAAP net operating loss was $15.5 million, compared to $15.0 million in the prior year period.
Net loss was $27.4 million, or ($0.32) net loss per share, compared to $32.3 million, or ($5.25) net loss per share, in the prior year period. Non-GAAP net loss was $13.3 million, or ($0.16) non-GAAP net loss per share, compared to $19.2 million, or ($3.11) non-GAAP net loss per share, in the prior year period.
Adjusted EBITDA was ($14.0) million, compared to ($13.6) million in the prior year period.
Cash, cash equivalents and investments totaled $254.9 million as of March 31, 2026.
For additional information regarding non-GAAP financial measures, see “Use of Non-GAAP Measures,” “Heartflow GAAP to Non-GAAP Reconciliations” and “Reconciliation of GAAP Net Loss to Adjusted EBITDA” below.
Webcast and Conference Call Details
Heartflow will host a conference call today, May 14, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its first quarter 2026 financial results. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a uniqu
See how HTFL stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "HTFL Heartflow Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.